Detalhe da pesquisa
1.
Trapping Poly(ADP-Ribose) Polymerase.
J Pharmacol Exp Ther
; 353(3): 446-57, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25758918
2.
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers.
Clin Drug Investig
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38698285
3.
Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease.
Clin Pharmacol Drug Dev
; 13(6): 696-709, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38363061
4.
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
Cancer Cell
; 6(6): 611-23, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15607965
5.
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor.
Sci Rep
; 11(1): 14486, 2021 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34262084
6.
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.
Front Pharmacol
; 11: 1066, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32848729
7.
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Mol Cancer Ther
; 16(12): 2735-2746, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28947502
8.
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Oncotarget
; 8(17): 28575-28587, 2017 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28212573
9.
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
J Med Chem
; 59(1): 335-57, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26652717
10.
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Oncotarget
; 7(47): 76534-76550, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27708213
11.
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
PLoS One
; 11(4): e0152584, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27055253
12.
Tumor-specific intravenous gene delivery using oncolytic adenoviruses.
Cancer Gene Ther
; 12(1): 19-25, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15514685
13.
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
Cancer Lett
; 343(2): 217-23, 2014 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24215868
14.
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
Acta Crystallogr F Struct Biol Commun
; 70(Pt 9): 1143-9, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25195882
15.
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
Clin Cancer Res
; 19(18): 5003-15, 2013 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23881923
16.
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Clin Cancer Res
; 19(22): 6322-8, 2013 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24077350
17.
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Cancer Res
; 66(19): 9736-43, 2006 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17018633
18.
Fighting cancer with vaccinia virus: teaching new tricks to an old dog.
Mol Ther
; 11(2): 180-95, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15668130
19.
Individualised cancer therapeutics: dream or reality? Therapeutics construction.
Expert Opin Biol Ther
; 5(11): 1427-41, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16255647
20.
Individualised cancer therapeutics: dream or reality?
Expert Opin Ther Targets
; 9(6): 1189-201, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16300470